Browse the evidence

Semaglutide treatment following catheter ablation for atrial fibrillation is associated with a lower rate of atrial arrhythmia recurrence over 12 months (hazard ratio, 0.68; P =0.030).

Practitioners may consider semaglutide as a therapeutic option to reduce atrial arrhythmia recurrence post-ablation.

Semaglutide treatment led to larger reductions in glycated hemoglobin levels compared to the control group (−1.3% vs. −0.6%; P <0.001).

Semaglutide may improve glycemic control in patients post-ablation.

Multidisciplinary combined therapy enhances the long-term efficacy of bariatric surgery.

Incorporating multidisciplinary approaches can improve patient outcomes post-surgery.

Caloric reduction may exacerbate nutrient inadequacies among adults with overweight or obesity.

Practitioners should consider the potential for nutrient deficiencies when advising caloric restriction for weight loss.

After a simulated 30% caloric reduction, 25%–40% of the population had intakes below the EAR for protein, vitamin B-6, and zinc.

Practitioners should monitor specific nutrient intakes when implementing caloric reductions.

Long-acting GLP-1 pharmacological agents have been approved for the treatment of obesity.

Practitioners can consider long-acting GLP-1 agents as viable options for obesity management.

Macronutrients and micronutrients influence cardiovascular disease (CVD).

Nutritional recommendations for CVD prevention should include a focus on both macronutrients and micronutrients.

In men, a 14.4% ILI-associated increase in total testosterone at year 1 mediated increases in weight (189 g; 95% CI, 65-317) and waist circumference (0.135 cm; 95% CI, 0.19-0.248) at year 4.

Practitioners should consider the role of testosterone in managing weight and waist circumference in men with type 2 diabetes.

In women, a 21.8% decrease in bioavailable testosterone at year 1 mediated decreases in whole-body fat mass (-164; 95% CI, -326 to -29.3), whole-body lean mass (-115 g; 95% CI, -203.4 to -40), and trunk lean mass (-97.2 g; 95% CI, -156 to -45.5) at year 4.

Practitioners should consider the role of bioavailable testosterone in managing body composition in women with type 2 diabetes.

The study revealed sex-specific mediating effects of sex hormones due to weight loss from intensive lifestyle intervention on body composition changes in people with type 2 diabetes.

Practitioners should tailor weight loss recommendations based on sex differences in hormone responses.

TGD patients frequently present to their endocrinologists for individualized, gender-affirming support to meet BMI cutoffs for GAS.

Endocrinologists should provide tailored support to help TGD patients achieve necessary BMI for GAS.

Multidisciplinary management considerations are offered for clinicians to assist TGD patients with obesity navigate BMI requirements to access GAS.

Clinicians should adopt a multidisciplinary approach to support TGD patients in meeting BMI requirements for GAS.

Participants improved their accuracy in estimating repetitions in reserve (RIR) during the bench press over the intervention.

Improving RIR estimation can enhance training effectiveness and safety.

Satellite cell activation was similar between groups in the untrained state but showed a trend toward greater increases with MIS after RET.

There may be potential benefits of multi-ingredient supplementation on satellite cell activation post-exercise.

The intake of saturated fatty acids (SAFAs) is directly associated with coronary heart disease (CHD) mortality, with a hazard ratio of 1.28 for one standard deviation increase.

Practitioners should consider the impact of saturated fat intake on heart disease risk in middle-aged men.

The intake of mono-unsaturated fatty acids (MUFAs) is inversely associated with coronary heart disease (CHD) mortality, with a hazard ratio of 0.84 for one standard deviation increase.

Practitioners should encourage the intake of mono-unsaturated fats to potentially lower heart disease risk.

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT may not be effective, some improvement in menstrual frequency can occur over time.

Tirzepatide is linked to a significantly reduced risk of overall hematologic malignancy (OR = 0.14, 95%CI = 0.03-0.60), particularly for lymphoma.

Tirzepatide may be a safer option for patients concerned about hematologic malignancies.

Semaglutide demonstrated an SAE incidence of 8.9%, compared to 6.2% for Liraglutide.

Practitioners should be aware of the SAE incidence when prescribing these medications.

Discontinuation rates due to adverse effects were 10.3% for Semaglutide and 8.3% for Liraglutide.

Practitioners should consider these discontinuation rates when evaluating treatment options.

49% of patients receiving semaglutide treatment had a full stomach compared to 18% of matched controls.

Clinicians should be aware of the increased risk of full stomach in patients on semaglutide during pre-operative assessments.

Chronic low-grade inflammation underlies psoriasis and hidradenitis suppurativa, which can worsen with obesity.

Weight management is crucial for patients with these skin diseases to prevent worsening of their conditions.

GLP-1a therapy was associated with a mean change in body mass index (BMI) of −0.83 kg/m2 in treated patients compared to −0.70 kg/m2 in those without GLP-1a therapy.

GLP-1a therapy may lead to modest reductions in BMI in a real-world setting.

In clinical practice, GLP-1a therapy was associated with more modest reductions in weight and HbA1c than shown in prior RCTs.

Practitioners should be aware that real-world outcomes may differ from clinical trial results.